A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain

A Phase 2, Enriched-Enrollment, Randomized-Withdrawal, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Tolerability, and Safety of NKTR-181 in Opioid-Naïve Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

NKTR-181 is being developed as an analgesic compound for the treatment of moderate to severe chronic pain - active as a mu agonist, but with inherent molecular properties designed to provide a unique clinical profile, including most notably, reduced CNS side effects and an attenuated attractiveness as a target of abuse.

Study Overview

• Status: Completed
• Conditions: Osteoarthritis of the Knee
• Intervention / Treatment: Drug: NKTR-181; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 296
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Mobile, Alabama, United States, 36608
      • Investigator Site - Mobile
  • Arizona
    • Tucson, Arizona, United States, 85704
      • Investigator Site - Tuscon
  • California
    • Garden Grove, California, United States, 92844
      • Investigator Site - Garden Grove
    • San Diego, California, United States, 92103
      • Investigator Site - San Diego
    • Walnut Creek, California, United States, 94598
      • Investigator Site - Walnut Creek
    • Westlake Village, California, United States, 91361
      • Investigator Site - Westlake Village
  • Florida
    • Coral Gables, Florida, United States, 33134
      • Investigator Site - Coral Gables
    • Fort Myers, Florida, United States, 33916
      • Investigator Site - Fort Meyers
    • Pembroke Pines, Florida, United States, 33028
      • Investigator Site - Pembroke Pines
    • West Palm Beach, Florida, United States, 33409
      • Investigator Site - West Palm Beach
    • Weston, Florida, United States, 33331
      • Investigator Site - Weston
  • Indiana
    • Evansville, Indiana, United States, 47714
      • Investigator Site - Evansville
  • Kansas
    • Wichita, Kansas, United States, 67207
      • Investigator Site - Wichita
  • Kentucky
    • Louisville, Kentucky, United States, 40213
      • Investigator Site - Louisville
  • Massachusetts
    • Brockton, Massachusetts, United States, 02301
      • Investigator Site - Brockton
    • Worcester, Massachusetts, United States, 01605
      • Investigator Site - Worcester
  • Missouri
    • Kansas City, Missouri, United States, 64114
      • Investigator Site - Kansas City
  • Nebraska
    • Omaha, Nebraska, United States, 68134
      • Investigator Site - Omaha
  • Nevada
    • Las Vegas, Nevada, United States, 89102
      • Investigator Site - Las Vegas
    • Las Vegas, Nevada, United States, 89119
      • Investigator Site - Las Vegas
  • New Jersey
    • Berlin, New Jersey, United States, 08009
      • Investigator Site - Berlin
    • Englewood, New Jersey, United States, 07631
      • Investigator Site - Englewood
  • North Carolina
    • Greensboro, North Carolina, United States, 27410
      • Investigator Site - Greensboro
  • Ohio
    • Cincinnati, Ohio, United States, 45219
      • Investigator Site - Cincinnati
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73109
      • Investigator Site - Oklahoma City
  • Pennsylvania
    • Duncansville, Pennsylvania, United States, 16635
      • Investigator Site - Duncansville
    • Philadelphia, Pennsylvania, United States, 19139
      • Investigator Site - Philadelphia
  • South Carolina
    • Charleston, South Carolina, United States, 29406
      • Investigator Site - Charleston
  • Texas
    • Austin, Texas, United States, 78705
      • Investigator Site - Austin
    • Dallas, Texas, United States, 75231
      • Investigator Site - Dallas
    • San Antonio, Texas, United States, 78205
      • Investigator Site - San Antonio
    • San Antonio, Texas, United States, 78209
      • Investigator Site - San Antonio
  • Utah
    • Salt Lake City, Utah, United States, 84106
      • Investigator Site - Salt Lake City
  • Wisconsin
    • Kenosha, Wisconsin, United States, 53142
      • Investigator Site - Kenosha

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Willing and able to give written informed consent;
• Willing and able to understand the study procedures, and comply with all study procedures;
• Females or males, age ≥ 18 years old;
• Body mass index 18-39, inclusive;
• In good general health;
• Clinical diagnosis of OA in one or both knees;
• Have been on a stable regimen of pain medication for the management of OA knee pain;
• Not experiencing adequate pain relief with their current dosing regimen;
• Women of childbearing potential (WCBP) must agree to use highly effective methods of birth control. Male subjects must agree to use contraception.

Exclusion Criteria:

• Females who are pregnant or lactating;
• Known history of hypersensitivity, intolerance, or allergy to opioids;
• Diagnosed as having any chronic pain symptom that in the Investigator's opinion would interfere with the assessment of pain and other symptoms of OA;
• Presence of any medical condition that would preclude study participation in the opinion of the investigator;
• Clinically significant abnormalities of vital signs or clinical laboratory results;
• Clinically significant electrocardiographic abnormalities;
• Received systemic corticosteroids within 30 days prior to signing the consent form;
• Subjects who are known or suspected to be currently abusing alcohol or drugs;
• Positive urine drug screen, or alcohol breath test during Screening Period testing;
• Positive serology for the surface antigen of Hepatitis B (HBsAg) or Hepatitis C (anti-HCV) during Screening Period testing;
• Known to be human immunodeficiency virus (HIV) positive;
• Donation of blood or plasma within 30 days prior to signing the consent form;
• Participation in another drug or biologic study within 30 days prior to signing the consent form;
• Any other reason that, in the opinion of the Investigator or Medical Monitor, would render the subject unsuitable for participation in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 100 mg NKTR-181; 100 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days.	Drug: NKTR-181
Experimental: 200 mg NKTR-181; 200 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days.	Drug: NKTR-181
Experimental: 300 mg NKTR-181; 300 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days	Drug: NKTR-181
Experimental: 400 mg NKTR-181; 400 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days	Drug: NKTR-181
Placebo Comparator: Placebo; Placebo dosing will be only in the double-blind randomization arm and will be identical in form to the Experimental NKTR-181.	Drug: Placebo; Placebo dosing will be only in the double-blind randomization arm and will be identical in form to the Experimental NKTR-181

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The Mean Change From Baseline Pain Score to Pain Score at the End of the Double-blind Randomized Treatment Period.	The first phase of this trial involved an open-label titration period where patients were given NKTR-181 at increasing doses up to a maximum of 400 mg twice daily until adequate pain control was achieved. Patients achieving adequate pain control were then progressed to the second phase of the trial where patients were randomized in a 1:1 ratio to receive either placebo or their tolerable dose level of NKTR-181. All efficacy data for NKTR-181 patients was combined into one group regardless of tolerable dose level. For this outcome, the subjects had to rate their worst pain intensity during the past 4 hours from 0 to 10 on an 11-point scale, where 0 represented one end of the continuum (i.e., no pain) and 10 represented the other extreme of pain intensity (i.e., worst pain imaginable).	Baseline and Visit 10 (day 69)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to Discontinuation During the Double-blind Randomized Treatment Period for Any Reason	The first phase of this trial involved an open-label titration period where patients were given NKTR-181 at increasing doses up to a maximum of 400 mg twice daily until adequate pain control was achieved. Patients achieving adequate pain control were then progressed to the second phase of the trial where patients were randomized in a 1:1 ratio to receive either placebo or their tolerable dose level of NKTR-181. All efficacy data for NKTR-181 patients was combined into one group regardless of tolerable dose level.	Randomization Treatment period is 24 days

Collaborators and Investigators

• Sponsor: Nektar Therapeutics

Study record dates

Study Major Dates

• Study Start: June 1, 2012
• Primary Completion (Actual): August 1, 2013
• Study Completion (Actual): September 1, 2013

Study Registration Dates

• First Submitted: June 12, 2012
• First Submitted That Met QC Criteria: June 12, 2012
• First Posted (Estimate): June 14, 2012

Study Record Updates

• Last Update Posted (Actual): August 2, 2021
• Last Update Submitted That Met QC Criteria: July 9, 2021
• Last Verified: July 1, 2021

More Information

Terms related to this study

• Keywords: Nektar; NKTR-181
• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis; Osteoarthritis, Knee
• Other Study ID Numbers: 12-181-04

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No